Context: The term pseudohypoparathyroidism (PHP) was coined to describe the clinical condition resulting from end-organ resistance to parathormone (rPTH), caused by genetic and/or epigenetic alterations within or upstream of GNAS. Although knowledge about PHP is growing, there are few data on the prevalence of underlying molecular defects. Objective: The purpose of our study was to ascertain the relative prevalence of PHP-associated molecular defects. Design: With a specially designed questionnaire, we collected data from all patients (n = 407) clinically and molecularly characterized to date by expert referral centers in France, Italy, and Spain. Results: Isolated rPTH (126/407, 31%) was caused only by epigenetic defects, 70% of patients showing loss of imprinting affecting all four GNAS differentially methylated regions and 30% loss of methylation restricted to the GNAS A/B:TSS-DMR. Multihormone resistance with no Albright's hereditary osteodystrophy (AHO) signs (61/407, 15%) was essentially due to epigenetic defects, although 10% of patients had point mutations. In patients with rPTH and AHO (40/407, 10%), the rate of point mutations was higher (28%) and methylation defects lower (about 70%). In patients with multihormone resistance and AHO (155/407, 38%), all types of molecular defects appeared with different frequencies. Finally, isolated AHO (18/407, 4%) and progressive osseous heteroplasia (7/407, 2%) were exclusively caused by point mutations. Conclusion: With European data, we have established the prevalence of various genetic and epigenetic lesions in PHP-affected patients. Using these findings, we will develop objective criteria to guide cost-effective strategies for genetic testing and explore the implications for management and prognosis.

The prevalence of GNAS deficiency-related diseases in a large cohort of patients characterized by the EuroPHP network / F.M. Elli, A. Linglart, I. Garin, L. De Sanctis, P. Bordogna, V. Grybek, A. Pereda, F. Giachero, E. Verrua, P. Hanna, G. Mantovani, G.P. De Nanclares. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. - ISSN 0021-972X. - 101:10(2016), pp. 3657-3668. [10.1210/jc.2015-4310]

The prevalence of GNAS deficiency-related diseases in a large cohort of patients characterized by the EuroPHP network

F.M. Elli
Primo
;
G. Mantovani
;
2016

Abstract

Context: The term pseudohypoparathyroidism (PHP) was coined to describe the clinical condition resulting from end-organ resistance to parathormone (rPTH), caused by genetic and/or epigenetic alterations within or upstream of GNAS. Although knowledge about PHP is growing, there are few data on the prevalence of underlying molecular defects. Objective: The purpose of our study was to ascertain the relative prevalence of PHP-associated molecular defects. Design: With a specially designed questionnaire, we collected data from all patients (n = 407) clinically and molecularly characterized to date by expert referral centers in France, Italy, and Spain. Results: Isolated rPTH (126/407, 31%) was caused only by epigenetic defects, 70% of patients showing loss of imprinting affecting all four GNAS differentially methylated regions and 30% loss of methylation restricted to the GNAS A/B:TSS-DMR. Multihormone resistance with no Albright's hereditary osteodystrophy (AHO) signs (61/407, 15%) was essentially due to epigenetic defects, although 10% of patients had point mutations. In patients with rPTH and AHO (40/407, 10%), the rate of point mutations was higher (28%) and methylation defects lower (about 70%). In patients with multihormone resistance and AHO (155/407, 38%), all types of molecular defects appeared with different frequencies. Finally, isolated AHO (18/407, 4%) and progressive osseous heteroplasia (7/407, 2%) were exclusively caused by point mutations. Conclusion: With European data, we have established the prevalence of various genetic and epigenetic lesions in PHP-affected patients. Using these findings, we will develop objective criteria to guide cost-effective strategies for genetic testing and explore the implications for management and prognosis.
English
endocrinology; diabetes and metabolism; biochemistry; endocrinology; clinical biochemistry; biochemistry (medical)
Settore MED/13 - Endocrinologia
Articolo
Esperti anonimi
Ricerca applicata
Pubblicazione scientifica
2016
Endocrine Society
101
10
3657
3668
12
Pubblicato
Periodico con rilevanza internazionale
scopus
pubmed
crossref
Aderisco
info:eu-repo/semantics/article
The prevalence of GNAS deficiency-related diseases in a large cohort of patients characterized by the EuroPHP network / F.M. Elli, A. Linglart, I. Garin, L. De Sanctis, P. Bordogna, V. Grybek, A. Pereda, F. Giachero, E. Verrua, P. Hanna, G. Mantovani, G.P. De Nanclares. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. - ISSN 0021-972X. - 101:10(2016), pp. 3657-3668. [10.1210/jc.2015-4310]
open
Prodotti della ricerca::01 - Articolo su periodico
12
262
Article (author)
no
F.M. Elli, A. Linglart, I. Garin, L. De Sanctis, P. Bordogna, V. Grybek, A. Pereda, F. Giachero, E. Verrua, P. Hanna, G. Mantovani, G.P. De Nanclares...espandi
File in questo prodotto:
File Dimensione Formato  
Elli Prevalence JCEM.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.81 MB
Formato Adobe PDF
1.81 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/456271
Citazioni
  • ???jsp.display-item.citation.pmc??? 46
  • Scopus 72
  • ???jsp.display-item.citation.isi??? 58
  • OpenAlex ND
social impact